Dead equity is ownership held by someone who no longer contributes to the company. In practice, it almost always means one thing: a cofounder who left, months or years ago, still owns a founder-sized slice of the business the remaining team is building without them.
I met dead equity in my case files more often than any other single problem, and I watched it do something remarkable: kill financings for companies that were otherwise thriving. Understanding why investors react so strongly to it is the fastest way to understand why prevention is worth one page of writing on day one.
Why investors walk
Three reasons, in ascending order of severity.
The arithmetic. Every point of dead equity dilutes everyone, forever, and buys nothing. An investor pricing a round looks at a cap table where twenty percent belongs to someone who left in year one, and reads it correctly: the people actually building own twenty points less motivation, and every future round compounds the waste.
The incentive problem. The remaining founders are working for years to enrich, in part, someone who walked away. Investors know exactly what that does to morale over a long company-building journey, because they have watched it before.
The signal. This is the one founders underestimate. Dead equity tells the investor a story about the team: they did not put vesting in place, they could not resolve the departure cleanly, and the person who left had enough leverage, or the team had little enough paperwork, that the equity stayed. None of that is the story you want told in diligence. Some investors will negotiate around dead equity. Many simply pass, because the next deal in their inbox does not have the problem.
How dead equity is born
Almost always the same sequence, and I could recite it from memory before opening a new file. Two or three founders start. No vesting, or vesting agreed verbally, or a template signed and forgotten. One founder drifts away in the hard middle stretch. Nobody wants the confrontation, so nothing is documented. The company survives anyway, which is when the departed equity transforms from an awkward loose end into a priced asset: the moment a round or an acquisition appears, the absent holder's signature suddenly has a market value, and they know it.
The tragedy is that none of this requires malice. It only requires silence, plus time, plus success.
Prevention costs one page. The cure costs the company.
Prevention is the founder agreement you sign at the start: vesting with a cliff, so unearned equity returns automatically when someone leaves; leaver provisions, so the manner of departure has consequences written in advance; and a buyback at a pre-agreed price formula, so the equity has a path home that does not depend on anyone's goodwill on a bad day.
The cure, once dead equity exists, is negotiation with someone who holds all the leverage: a buyout at whatever price the absent holder will accept, sometimes funded by the round itself, sometimes litigated for years. I billed those years. The price of the cure is routinely a hundred times the price of the prevention, and that ratio is the most honest one-line argument for signing a founder agreement I know.